1. adults or proxy unable to consent 2. individuals who are not yet adults (infants, children, teenagers) 3. pregnant women 4. prisoners 5. patients expected to die within 24 hours or with a "do not resuscitate" order, 6. multi-organ failure, 7. history of hypersensitivity or allergy to any component of the study drug, 8. ongoing massive surgical or unexplained bleeding, 9. history of bleeding or clotting disorder, 10. severe traumatic brain injury (glasgow coma scale \<6), 11. spinal or multiple-trauma, 12. cancer (incurable/terminal phase) and/or patients receiving palliative care, 13. enrollment in another concurrent clinical interventional study if considered interfering with this study objectives 14. per study team discretion, any condition(s) that may prevent safe treatment, preclude adequate evaluation or adding further risk to their underlying illness.

1. adults or proxy unable to consent 2. individuals who are not yet adults (infants, children, teenagers) 3. pregnant women 4. prisoners 5. patients expected to die within 24 hours or with a "do not resuscitate" order, 6. multi-organ failure, 7. history of hypersensitivity or allergy to any component of the study drug, 8. ongoing massive surgical or unexplained bleeding, 9. history of bleeding or clotting disorder, 10. severe traumatic brain injury (glasgow coma scale \<6), 11. spinal or multiple-trauma, 12. cancer (incurable/terminal phase) and/or patients receiving palliative care, 13. enrollment in another concurrent clinical interventional study if considered interfering with this study objectives 14. per study team discretion, any condition(s) that may prevent safe treatment, preclude adequate evaluation or adding further risk to their underlying illness.

adults or proxy unable to consent individuals who are not yet adults (infants, children, teenagers) pregnant women prisoners patients expected to die within 24 hours or with a "do not resuscitate" order, multi-organ failure, history of hypersensitivity or allergy to any component of the study drug, ongoing massive surgical or unexplained bleeding, history of bleeding or clotting disorder, severe traumatic brain injury (glasgow coma scale <6), spinal or multiple-trauma, cancer (incurable/terminal phase) and/or patients receiving palliative care, enrollment in another concurrent clinical interventional study if considered interfering with this study objectives per study team discretion, any condition(s) that may prevent safe treatment, preclude adequate evaluation or adding further risk to their underlying illness.

adults or proxy unable to consent individuals who are not yet adults (infants, children, teenagers) pregnant women prisoners patients expected to die within 24 hours or with a "do not resuscitate" order, multi-organ failure, history of hypersensitivity or allergy to any component of the study drug, ongoing massive surgical or unexplained bleeding, history of bleeding or clotting disorder, severe traumatic brain injury (glasgow coma scale <6), spinal or multiple-trauma, cancer (incurable/terminal phase) and/or patients receiving palliative care, enrollment in another concurrent clinical interventional study if considered interfering with this study objectives per study team discretion, any condition(s) that may prevent safe treatment, preclude adequate evaluation or adding further risk to their underlying illness.

1. adults or proxy unable to consent 2. individuals who are not yet adults (infants, children, teenagers) 3. pregnant women 4. prisoners 5. patients expected to die within 24 hours or with a "do not resuscitate" order, 6. multi-organ failure, 7. history of hypersensitivity or allergy to any component of the study drug, 8. ongoing massive surgical or unexplained bleeding, 9. history of bleeding or clotting disorder, 10. severe traumatic brain injury (glasgow coma scale <6), 11. spinal or multiple-trauma, 12. cancer (incurable/terminal phase) and/or patients receiving palliative care, 13. enrollment in another concurrent clinical interventional study if considered interfering with this study objectives 14. per study team discretion, any condition(s) that may prevent safe treatment, preclude adequate evaluation or adding further risk to their underlying illness.

1. adults or proxy unable to consent 2. individuals who are not yet adults (infants, children, teenagers) 3. pregnant women 4. prisoners 5. patients expected to die within 24 hours or with a "do not resuscitate" order, 6. multi-organ failure, 7. history of hypersensitivity or allergy to any component of the study drug, 8. ongoing massive surgical or unexplained bleeding, 9. history of bleeding or clotting disorder, 10. severe traumatic brain injury (glasgow coma scale <6), 11. spinal or multiple-trauma, 12. cancer (incurable/terminal phase) and/or patients receiving palliative care, 13. enrollment in another concurrent clinical interventional study if considered interfering with this study objectives 14. per study team discretion, any condition(s) that may prevent safe treatment, preclude adequate evaluation or adding further risk to their underlying illness.

1. adults unable to consent 2. individuals who are not yet adults (infants, children, teenagers) 3. pregnant women 4. prisoners 5. patients expected to die within 24 hours or with a "do not resuscitate" order, 6. multi-organ failure, 7. history of hypersensitivity or allergy to any component of the study drug, 8. ongoing massive surgical or unexplained bleeding, 9. history of bleeding or clotting disorder, 10. ongoing unfractionated heparin (ufh), low molecular weight heparin (lmwh), or anticoagulation treatment - (except for low-dose chemoprophylaxis), 11. severe traumatic brain injury (glasgow coma scale less than 6), 12. spinal or multiple-trauma, 13. cancer (incurable/terminal phase) and/or patients receiving palliative care, 14. enrollment in another concurrent clinical interventional study - if considered interfering with this study objectives

1. adults unable to consent 2. individuals who are not yet adults (infants, children, teenagers) 3. pregnant women 4. prisoners 5. patients expected to die within 24 hours or with a "do not resuscitate" order, 6. multi-organ failure, 7. history of hypersensitivity or allergy to any component of the study drug, 8. ongoing massive surgical or unexplained bleeding, 9. history of bleeding or clotting disorder, 10. ongoing unfractionated heparin (ufh), low molecular weight heparin (lmwh), or anticoagulation treatment - (except for low-dose chemoprophylaxis), 11. severe traumatic brain injury (glasgow coma scale less than 6), 12. spinal or multiple-trauma, 13. cancer (incurable/terminal phase) and/or patients receiving palliative care, 14. enrollment in another concurrent clinical interventional study - if considered interfering with this study objectives